Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZHWPG)

• Drug Name: ASTRAGALIN Drug Info
• Synonyms: Astragalin; 480-10-4; Astragaline; kaempferol-3-glucoside; Kaempferol 3-O-glucoside; Kaempferol 3-glucoside; Kaempferol-3-O-glucoside; asragalin; Kaempferol-3-beta-monoglucoside; Kaempferol-3-D-glucoside; Kaempferol-3-beta-glucopyranoside; UNII-APM8UQ3Z9O; 3,4',5,7-Tetrahydroxyflavone-3-glucoside; Kaempferol 3-O-beta-D-glucopyranoside; 3-Glucosylkaempferol; Kaempferol 3-O-beta-D-glucoside; APM8UQ3Z9O; 4H-1-Benzopyran-4-one, 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-; CHEMBL233930; CHEBI:30200

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5282102
  ChEBI ID: CHEBI:30200
  CAS Number: CAS 480-10-4
  TTD Drug ID: DMZHWPG

Molecule-Related Drug Atlas

Drug(s) Targeting Aldose reductase (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[3]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[4]
Fidarestat	DMZL1I8	Diabetic complication	5A2Y	Phase 3	[5]
Ranirestat	DMD5QRS	Diabetic neuropathy	8C0Z	Phase 3	[6]
CONTIGOSIDE B	DMX9V8K	Thrombosis	DB61-GB90	Phase 2/3	[7]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[6]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[8]
LIDORESTAT	DMA0RI9	Diabetic complication	5A2Y	Phase 2	[9]
QR-333	DMKVIWM	Diabetic neuropathy	8C0Z	Phase 2	[10]
ADMVA	DM819CO	Diabetic complication	5A2Y	Phase 2	[6]

Drug(s) Targeting Angiotensin-converting enzyme (ACE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[11]
Spirapril	DM5XLTY	Hypertension	BA00-BA04	Approved	[12]
Captopril	DM458UM	Chronic heart failure	BD1Z	Approved	[13]
Benazepril	DMH1M9B	Hypertension	BA00-BA04	Approved	[14]
Moexipril	DM26E4B	Hypertension	BA00-BA04	Approved	[15]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[16]
Perindopril	DMOPZDT	Hypertension	BA00-BA04	Approved	[17]
Trandolapril	DM4L6EU	Chronic heart failure	BD1Z	Approved	[18]
Fosinopril	DM9NJ52	Chronic heart failure	BD1Z	Approved	[19]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Inhibitor	[2]
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[1]

References

• [1] Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3.
• [2] Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5.
• [3] Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
• [4] Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
• [5] Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
• [7] Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
• [8] ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
• [9] Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
• [10] A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
• [11] Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
• [12] Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
• [13] Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
• [14] Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
• [15] Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
• [16] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [17] Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
• [18] Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
• [19] Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
• [20] Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.